Updated:
Genesis Capital
Genesis Capital is an investor in healthcare that partners with leading healthcare businesses to achieve transformational growth and positive health outcomes.
Genesis Capital
Genesis Capital is an investor in healthcare that partners with leading healthcare businesses to achieve transformational growth and positive health outcomes. It supports high-quality healthcare businesses led by ambitious founders and is thematically-led, investing in healthcare verticals with long-term tailwinds. Headquartered in Sydney, its portfolio spans Australia and New Zealand.
General information
Firm type
Private Equity
Year founded
2016
Location
Region
Oceania
Country
Australia
City
New York
Corporate office
Sydney, Australia
Principals
Chris Yoo
Founder & Managing Director
Dr. Michael Caristo
Founder & Managing Director
Michael Garcia
Managing Director - Finance & Operations
James Hamlin
Managing Director - Origination
Ashton Tay
Managing Director
Tara Hariharan
Associate Director
Thuy Thai
Associate Director
Ashleigh Lascelles
Finance Manager
Joseph Kozera
Investment Manager
Laura Parmegiani
Investment Manager
Mackenzie Jones
Investment Manager
Calvin Lam
Associate
Paul Han
Associate
Elaine Yan
Associate
Shaun Lonstein
Analyst
Fergal Dillon
Data Analyst
Nathan Green
Operating Partner
Ben Wang
Head of Technology
James Owen
Head of Data and AI
Corinne Salem
Office Manager
Justina Simes
Executive Assistant
David Gordon
Chair - Genesis Capital
Hon. Greg Hunt
Senior Advisor
Ian Maynard
Chair - AHTG
Sector focus
Frequently asked questions
What investment stages does Genesis Capital target?
Genesis Capital spans the full lifecycle of private-company finance. Its stated strategy covers early-stage seed and startup rounds, expansion and late-stage growth equity, and mature-company transactions including management buyouts, management buy-ins, and succession-driven recapitalizations. This breadth is unusual — most Australian firms segment into venture or buyout specialists.
What is Genesis Capital's track record or portfolio?
Specific portfolio companies, fund vintages, and return data are not publicly available. The firm maintains a minimal external footprint, with no disclosed case studies or named investments. Allocators evaluating Genesis should expect to rely entirely on direct due diligence and off-market references.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: